Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8936 results

  1. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development Reference number: GID-TA10279 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

    Awaiting development Reference number: GID-TA10431 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dulaglutide for treating type 2 diabetes [ID1451]

    Awaiting development Reference number: GID-TA10439 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development Reference number: GID-TA10446 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

    Awaiting development Reference number: GID-TA10453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development Reference number: GID-TA10606 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sotagliflozin for treating type 2 diabetes [ID1657]

    Awaiting development Reference number: GID-TA10665 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

    Awaiting development Reference number: GID-TA10685 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  13. Third molars (impacted) - prophylactic removal [ID898]

    In development Reference number: GID-TAG525 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

    Awaiting development Reference number: GID-TA10486 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development Reference number: GID-TA11494 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development